Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure

Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.

India’s top-ranked drug firm, Sun Pharmaceutical Industries Ltd., reported a decline in earnings for the fourth quarter ended March 2017 dented, in part, by the challenging generic pricing environment in the US and management commentary indicates a tough fiscal 2018 ahead.

Fourth quarter sales declined by 8% to INR68.25bn ($1.05bn) compared with the same period last year, with US finished dosage sales at $381m (-34%). Net profits slid 14% to INR12.23bn.

More from Business

More from Scrip